Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

(2020) Rita Cabrita et al.   NATURE

Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer

(2019) Vid Leko et al.   JOURNAL OF IMMUNOLOGY

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

(2019) Michael Fehlings et al.   Journal for ImmunoTherapy of Cancer

MHC-II neoantigens shape tumour immunity and response to immunotherapy

(2019) Elise Alspach et al.   NATURE

BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis

(2018) Eva Kaufmann et al.   CELL

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

(2018) Rob J.W. Arts et al.   Cell Host & Microbe

Mechanisms of BCG immunotherapy and its outlook for bladder cancer

(2018) Caroline Pettenati et al.   Nature Reviews Urology

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity

(2018) Elise Alspach et al.   Cold Spring Harbor Perspectives in Biology

White paper on microbial anti-cancer therapy and prevention

(2018) Neil S. Forbes et al.   Journal for ImmunoTherapy of Cancer

Cancer Neoantigens

(2018) Ton N. Schumacher et al.   Annual Review of Immunology

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

(2018) Praveen K. Bommareddy et al.   Science Translational Medicine

Current Clinical Trials in Non-muscle Invasive Bladder Cancer

(2018) Timo K. Nykopp et al.   Current Urology Reports

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells

(2017) M. Fehlings et al.   Nature Communications

Intravesical BCG Induces CD4 + T-Cell Expansion in an Immune Competent Model of Bladder Cancer

(2017) Max Kates et al.   Cancer Immunology Research

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

The mechanism of action of BCG therapy for bladder cancer—a current perspective

(2014) Gil Redelman-Sidi et al.   Nature Reviews Urology

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer

(2014) Kathrin Buffen et al.   PLoS Pathogens

Essential yet limited role for CCR2+ inflammatory monocytes during Mycobacterium tuberculosis-specific T cell priming

(2013) Miriam Samstein et al.   eLife

Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

(2012) C. Biot et al.   Science Translational Medicine

Inflammatory Monocytes Facilitate Adaptive CD4 T Cell Responses during Respiratory Fungal Infection

(2009) Tobias M. Hohl et al.   Cell Host & Microbe

Delayed protection by ESAT-6–specific effector CD4+T cells after airborneM. tuberculosisinfection

(2008) Alena M. Gallegos et al.   JOURNAL OF EXPERIMENTAL MEDICINE